$Recursion Pharmaceuticals(RXRX.US) Foreword: I personally believe in the potential of AI in pharmaceuticals and tend to think that RXRX has significant rebound potential. Over the past year, the price has been continuously suppressed. 2026 could be the year of its rise.

Report Date: January 30, 2026 Time Frame: January 23 to January 30, 2026 Perspective: As a long-term investor, this report focuses on the long-term growth potential of Recursion Pharmaceuticals Inc. The company is a clinical-stage TechBio enterprise that uses AI to decode biology for drug development. Information from the past week shows high stock volatility, but there are positive analyst upgrades and industry trends supporting it. The report is based on reliable sources and aims to provide comprehensive insights, including internal dynamics, business performance, collaborations, market sentiment, industry changes, and institutional views. Overall, despite short-term stock price pressure, the AI-driven drug discovery platform shows strong potential, with key data readouts and revenue growth expected in 2026.

Internal Dynamics

Recursion did not announce any major internal changes in the past week, but the leadership transition was completed on January 1, 2026: Co-founder Chris Gibson became Chairman of the Board, and Dr. Najat Khan took over as CEO and President. This change aims to drive the commercialization of the AI platform and advance the clinical pipeline. On January 27, the company’s official X account posted videos and updates highlighting cancer statistics (e.g., 1 in 5 people will develop cancer, 90% of clinical trials fail) and its AI methodology, referencing a Google podcast discussing its “Google Maps-style” biological mapping approach. The post received high engagement (64 likes, 7 reposts), showing the company’s active promotion of its mission: accelerating drug discovery using massive datasets, supercomputing, and an end-to-end AI platform. Additionally, the company presented at the J.P. Morgan Healthcare Conference on January 13, emphasizing AI-validated pipeline progress and partner milestones.

Long-term investor perspective: Stable leadership and AI platform enhancements indicate Recursion is shifting from R&D to commercialization, potentially reducing drug failure rates and improving efficiency.

Business Performance

Last week, RXRX showed significant volatility: a 10.8% rise to $4.98 on January 22 with ~10.6M shares traded, followed by a 4.64% drop to $4.73 on January 23. As of January 28, the market cap was ~$2.58B. The company expects 2026 revenue of $83M, a notable increase from $63M in 2025. The clinical pipeline includes REC-1245 (cancer drug, H1 data readout) and REC-102 (bone disease, H2 readout). The January 12 investor presentation highlighted a $755M cash reserve at the end of 2025, extending the cash runway to the end of 2027, with plans to reduce cash burn to under $390M in 2026 and cut operating expenses by 35% compared to 2024.

Long-term investor perspective: Despite an 80% revenue decline in 2025 (Q3: $5.18M), external validation of the AI platform (e.g., Sanofi, Roche collaborations) and potential milestone payments (>$100M by end-2026) support growth. Higher AI-driven drug discovery success rates could reduce development costs to $200M/drug.

Industry Collaborations & Client Feedback

No new collaborations were announced last week, but the company highlighted existing partnerships with Google Cloud and NVIDIA for processing massive cell image data (millions of experiments weekly). An X post mentioned a Google podcast collaboration showcasing how its platform shifts from disease to health states. Limited client feedback is available, but clinical trials like REC-4881’s TUPELO study showed positive results: median polyp burden reduction of 43% at 12 weeks, with 82% of patients maintaining reduction at 25 weeks. The company plans to discuss registration pathways with the FDA in H1.

Long-term investor perspective: Collaborations strengthen the AI ecosystem, potentially reducing animal testing and accelerating development. Positive client (e.g., patients, partners) responses to durable efficacy enhance pipeline value.

Market Sentiment

Market sentiment leans optimistic. On January 28, a Motley Fool article asked, “Can This Beaten-Down AI Stock Bounce Back in 2026?”, noting mid-term clinical data readouts could drive the stock but warning of uncertainty. Another article, “Forget 2025: These Growth Stocks Could Soar in 2026,” listed Recursion as a potential pick, emphasizing the proven value of AI drug discovery tech. On X, traders (e.g., @altjames13, @jacobftcth) recommended buying, calling it a “clinical-stage biotech with strong near-term growth.” A January 17 YouTube video analyzed trends, citing a senior biotech strategist’s report. Analyst consensus: Hold rating, $9.40 target; JPMorgan upgraded to Overweight, $11 target.

Long-term investor perspective: Sentiment reflects AI hype, but data readouts are key. The stock has high rebound potential after a 44% drop in 2025; clinical success could significantly revalue it.

Relevant Industry Shifts

The AI drug discovery industry is rapidly evolving. On January 26, Reuters reported pharma companies using AI to accelerate clinical trials and regulatory submissions, cutting weeks (e.g., Novartis reduced trial site selection from weeks to 2 hours). NVIDIA and Eli Lilly announced a $1B AI innovation lab to speed up drug discovery. Predictions show >50% of new drugs will be AI-developed by 2030; the FDA expects the first AI drug approval within 5 years. The global AI medical imaging market is $2.57T, while AI drug discovery is $1.81B. Insilico and Qilu expanded their partnership to use generative AI for cardiometabolic drugs.

Long-term investor perspective: The industry’s shift to AI-native models benefits Recursion, as its platform can compress timelines and lower costs. Quantum computing and synthetic biology integration could further amplify its edge.

Institutional Investor Views

Institutional ownership stands at 89.06%. Last week, Cathie Wood’s ARK Investment bought 755K shares, signaling confidence. Vanguard and ARK increased holdings in 2025 Q3 (Vanguard +3.7M shares). Seeking Alpha upgraded to Buy on December 18 (impact ongoing), citing institutional support for AI drug discovery and >$100M milestone payments by 2026. Insiders sold ~586K shares in Q4, but institutions dominate holdings.

Long-term investor perspective: High institutional ownership and ARK’s buying reflect long-term confidence in the AI platform. Despite short-term sales, clinical readouts are expected to attract more capital.

Conclusion & Investment Recommendation

Last week, Recursion’s dynamics were dominated by stock volatility and positive sentiment, with no major negative events. Its AI platform is well-positioned in the industry’s transformation, with 2026 data readouts and revenue growth as key catalysts. Risks include clinical failures and high burn rates, but cash reserves are sufficient. Long-term investors may consider holding or adding, targeting $9–11, with attention on H1 FDA interactions and clinical updates. Monitor industry AI advancements, such as NVIDIA collaborations, for indirect benefits.